Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia

Seoul National Hospital

Status: Unknown

Conditions: Schizophrenia; Genetic Polymorphism; Metabolic Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT00717509

snh003

Details and patient eligibility

About

We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.

Full description

The use of antipsychotics, especially clozapine and olanzapine is associated with metabolic side effects, which put patients with schizophrenia at risk for cardiovascular morbidity or diabetes.

The prevalence of the metabolic syndrome was 53.8% of patients who taking clozapine. The high interindividual variability in antipsychotic-induced metabolic abnormalities suggests that genetic makeup is a possible determinant.

The genotypes of the multiple gene such as HTR2C, LEP, adrenergic receptor,PPAR,GNB3 are suggested to have associations with the metabolic side effects (weight,glucose,lipid,BP,metabolic syndrome) in patients using antipsychotics.

We are going to investigate whether those multiple genetic polymorphisms are associated with the metabolic side effects in patients taking clozapine.

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 18-65
• who can understand and sign the informed consent

Exclusion criteria

• who refuse to participate this study

Trial design

150 participants in 1 patient group

clozapine group

Description:

* chronic schizophrenia * have been taking clozapine at leaset one year * without diabetes, pulmonary tuberculosis